Fibrinogen Heterogeneity in Homozygous Plasminogen Deficiency Type I: Further Evidence that Plasmin Is not Involved in Formation of LMW- and LMW’-Fibrinogen

Summary

Human plasma fibrinogen is heterogeneous in SDS-polyacrylamide gel electrophoresis and other methods for separation of proteins by molecular size. A high molecular weight fraction (HMW-fibrinogen, 340 kD) contributes approximately 50% of total fibrinogen antigen. Low molecular weight fibrinogen (LMW-fibrinogen, 300 kD) adds another 40%. The residual amount is LMW’-fibrinogen with a molecular weight of 280 kD, and a small amount of very high molecular weight fibrinogen (Fib420), the product of alternative splicing of the Aa-chain genetic information, resulting in an extended A?-chain C-terminus. Fibrinogen was detected by specific immunostaining of nonreduced SDS-PAGE gel immunoblots with antibodies against fibrinopeptide A. Using densitometric scans of the immunoblots we found a ratio of HMW-, LMW- and LMW’-fibrinogen in a patient with homozygous plasminogen deficiency that was similar to the ratio found in immunoblots of plasma from healthy blood donors. Treatment with plasminogen concentrate resulted in a slight decrease of the proportion of HMW-fibrinogen, followed by an increase to 78%. The LMW’- fibrinogen band gained intensity initially, increasing to 11.9% of fibrinogen antigen 6 h after starting plasminogen infusion, but then dropped to levels below detection limit of the immunoblotting assay. LMW-fibrinogen remained constant during the initial 72 h of plasminogen treatment, then dropping to values in the range of 22-25% afterwards. The proportion of HMW-, LMW-, and LMW’-fibrinogen.again reached the initial levels two weeks after starting treatment with plasminogen concentrate. We conclude that plasminogen is not involved in the limited proteolysis leading to formation of LMW-fibrinogen and LMW’-fibrinogen in the absence of a generalized fibrinolytic condition. Fibrinolytic activation may lead to the formation of fibrinogen degradation product X, which appears in a similar position as LMW’- fibrinogen in SDS-PAGE.

• References

• 1 Finlayson JS, Mosesson MW. Heterogeneity of human fibrinogen. Biochemistry 1963; 2: 42-46
• 2 Mills D, Karpatkin S. The non-plasmin, proteolytic origin of human fibrinogen heterogeneity. Biochim Biophys Acta 1971; 251: 121-125
• 3 Lipinska I, Lipinski B, Gurewich V. Fibrinogen heterogeneity in human plasma. Electrophoretic demonstration and characterization of two major components. J Lab Clin Med 1974; 84: 509-516
• 4 Holm B, Godal HC. Quantitation of the three normally-occurring plasma fibrinogens in health and during so-called “acute phase” by SDS electrophoresis of fibrin obtained from EDTA-plasma. Thromb Res 1984; 35: 279-290
• 5 Fu Y, Weissbach L, Plant PW, Oddoux C, Cao Y, Liang TJ, Roy SN, Redman CM, Grieninger G. Carboxy-terminal-extended variant of the human fibrinogen alpha subunit: a novel exon conferring marked homology to beta and gamma subunits. Biochemistry 1992; 31: 11968-11972
• 6 Fu Y, Grieninger G. Fib 420: a normal human variant of fibrinogen with two extended alpha chains. Proc Natl Acad Sci USA 1994; 91: 2625-2628
• 7 Gaffney PJ. The molecular and functional condition of plasma fibrinogen during thrombolytic therapy with streptokinase (SK). Thromb Res 1973; 2: 105-114
• 8 Mosesson MW. The fibrinogenolytic pathway of fibrinogen catabolism. Thromb Res 1973; 2: 185-200
• 9 Mosesson MW, Finlayson JS, Umfleet RA. Human fibrinogen heterogeneities. I. Structural and related studies of plasma fibrinogens which are high solubility catabolic intermediates. J Biol Chem 1972; 247: 5210-5219
• 10 Nakashima A, Sasaki S, Miyazaki K, Miyata T, Iwanaga S. Human fibrinogen heterogeneity: the COOH-terminal residues of defective A alpha chains of fibrinogen II. Blood Coagul Fibrinolysis 1992; 3: 361-370
• 11 Cohen SR. Ligneous conjunctivitis: an ophthalmic disease with potentially fatal tracheobronchial obstruction. Ann Otol Rhinol Laryngol 1990; 99: 509-512
• 12 Bronwyn BatemanJ, Isenberg SJ, Pettit TH, Simons KB. Ligneous Conjunctivitis: an Autosomal Recessive Disorder. J Ped Ophtal Strab 1986; 23: 137-140
• 13 Firat T. Ligneous conjunctivitis. Am J Ophthalmol 1974; 78: 679-688
• 14 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
• 15 Becker U, Bartl K, Wahlefeld AW. A functional photometric assay for plasma fibrinogen. Thromb Res 1984; 35: 475-484
• 16 Kario K, Matsuo T, Kabayashi H, Matsuo M, Yamamoto K, Sakurai G, Baba M. Rapid quantitative evaluation of plasma D-dimer levels in thrombotic states using an automated latex photometric immunoassay. Thromb Res 1992; 66: 179-189
• 17 Adema E, Gebert U. Pooled patient samples as reference material for D-Dimer. Thromb Res 1995; 80: 85-88
• 18 Firat T, Tinaztepe B. Histochemical Investigations on Ligneous Conjunctivitis and a New Method of Treatment. Acta Ophthalmol Copenh 1970; 48: 03-13
• 19 Akerlund A, Greiff L, Andersson M, Bende M, Alkner U, Persson CG. Mucosal exudation of fibrinogen in coronavirus-induced common colds. Acta Otolaryngol Stockh 1993; 113: 642-648
• 20 Fahy JV, Liu J, Wong H, Boushey HA. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am Rev RespirDis 1993; 147: 1126-1131
• 21 Mosesson MW. Fibrinogen heterogeneity. Ann N Y Acad Sci 1983; 408: 097-113
• 22 Holm B, Brosstad F, Kierulf P, Godal HC. Polymerization properties of two normally circulating fibrinogens, HMW and LMW. Evidence that the COOH-terminal end of the a-chain is of importance for fibrin polymerization. Thromb Res 1985; 39: 595-606
• 23 Holm B, Nilsen DW, Kierulf P, Godal HC. Purification and characterization of 3 fibrinogens with different molecular weights obtained from normal human plasma. Thromb Res 1985; 37: 165-176
• 24 Copley AL. The physiological significance of the endoendothelial fibrin lining (EEFL) as the critical interface in the “vessel-blood organ” and the importance of in vivo “fibrinogenin formation” in health and disease. Thromb Res Suppl 1983; 5: 105-145
• 25 Princen HM, Moshage HJ, Emeis JJ, de HaardHJ, Nieuwenhuizen W, Yap SH. Fibrinogen fragments X, Y, D and E increase levels of plasma fibrinogen and liver mRNAs coding for fibrinogen polypeptides in rats. Thromb Haemost 1985; 53: 212-215
• 26 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J Clin Invest 1990; 86: 385-391
• 27 Goto S, Kawai Y, Abe S, Takahashi E, Handa S, Ogawa S, Watanabe K, Hori S, Ikeda Y. Serial changes in coagulant activities after thrombolytic therapy for acute myocardial infarction. Angiology 1994; 45: 273-281
• 28 Seitz R, Lerch L, Immel A, Egbring R. D-dimer tests detect both plasmin and neutrophil elastase derived split products. Ann Clin Biochem 1995; 32: 193-195
• 29 Matsuda M, Terukina S, Yamazumi K, Maekawa H, Soe G. A monoclonal antibody that recognizes the NH2-terminal conformation of fragment D. Excerpta medica 1990; 892: 43-48
• 30 Bos R, van LeuvenCJ, Stolk J, Hiemstra PS, Dijkman JH, Nieuwenhuizen W. A monoclonal antibody with high affinity for a neo-antigenic site in fibrinogen degraded by polymorphonuclear leukocyte-derived elastase. Blood Coagul Fibrinolysis 1995; 6: 259-267